BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rochman M, Xie YM, Mack L, Caldwell JM, Klingler AM, Osswald GA, Azouz NP, Rothenberg ME. Broad transcriptional response of the human esophageal epithelium to proton pump inhibitors. J Allergy Clin Immunol 2021;147:1924-35. [PMID: 33289661 DOI: 10.1016/j.jaci.2020.09.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lucendo AJ, Molina-Infante J. Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. Expert Rev Clin Immunol 2022;:1-14. [PMID: 35770955 DOI: 10.1080/1744666X.2022.2096591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Choi HG, Min C, Yoo DM, Tan BK, Kim J, Kim HI, Park J, Park S, Hwang YI, Jang SH, Jung K. Associations Between Asthma Diagnosis/Asthma Exacerbation and Previous Proton-Pump Inhibitor use: A Nested Case-Control Study Using a National Health Screening Cohort. Front Pharmacol 2022;13:888610. [DOI: 10.3389/fphar.2022.888610] [Reference Citation Analysis]
3 Thakkar KP, Fowler M, Keene S, Iuga A, Dellon ES. Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis. Dig Liver Dis 2022:S1590-8658(22)00209-2. [PMID: 35410852 DOI: 10.1016/j.dld.2022.03.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Franciosi JP, Mougey EB, Dellon ES, Gutierrez-junquera C, Fernandez-fernandez S, Venkatesh RD, Gupta SK. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. JAA 2022;Volume 15:281-302. [DOI: 10.2147/jaa.s274524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Dan W, Peng L, Yan B, Li Z, Pan F. Human Microbiota in Esophageal Adenocarcinoma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Implications. Front Microbiol 2022;12:791274. [DOI: 10.3389/fmicb.2021.791274] [Reference Citation Analysis]
6 Dunn JLM, Rothenberg ME. 2021 year in review: Spotlight on eosinophils. J Allergy Clin Immunol 2021:S0091-6749(21)01796-6. [PMID: 34838883 DOI: 10.1016/j.jaci.2021.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shoda T, Wen T, Caldwell JM, Ben-Baruch Morgenstern N, Osswald GA, Rochman M, Mack LE, Felton JM, Abonia JP, Arva NC, Atkins D, Bonis PA, Capocelli KE, Collins MH, Dellon ES, Falk GW, Gonsalves N, Gupta SK, Hirano I, Leung J, Menard-Katcher PA, Mukkada VA, Putnam PE, Rudman Spergel AK, Spergel JM, Wechsler JB, Yang GY, Aceves SS, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators Group. Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk. Gastroenterology 2021:S0016-5085(21)03653-2. [PMID: 34687736 DOI: 10.1053/j.gastro.2021.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Oliva S, Dellon ES. Reversal of fibrosis in eosinophilic esophagitis: Another feather in the PPI cap? Dig Liver Dis 2021;53:1476-8. [PMID: 34531128 DOI: 10.1016/j.dld.2021.08.012] [Reference Citation Analysis]
9 Chehade M, Aceves SS. Treatment of Eosinophilic Esophagitis: Diet or Medication? The Journal of Allergy and Clinical Immunology: In Practice 2021;9:3249-56. [DOI: 10.1016/j.jaip.2021.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ganeshanandan L, Lucas M. Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae. Int J Mol Sci 2021;22:1127. [PMID: 33498771 DOI: 10.3390/ijms22031127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]